The company manufactures and exports phthalocyanine blue pigments and chemicals used in industrial applications such as paints, textiles, inks, and plastics.
The company operates in a commoditized chemical segment with no evidence of a moat. Low and volatile margins, combined with a recent interest coverage ratio below 1.0, indicate a lack of pricing power and high sensitivity to raw material and energy costs.
Capital is being heavily deployed into a new sulphuric acid and chemical intermediate project, significantly increasing debt and capital work-in-progress. Historically, reinvestment has not translated into consistent EPS growth, with a long-term EPS CAGR of -41.9%.
The company's aggressive expansion into sulphuric acid, funded by heavy debt, proved to be a value-destroying trap as the new capacity came online during a cyclical downturn. With an interest coverage ratio already below one, the business was unable to service its obligations, leading to a liquidity crunch and significant equity dilution. The historical inability to convert capital into earnings growth persisted, and the capital tied up in related-party advances remained unrecoverable, leaving shareholders with a hollowed-out balance sheet and a business model that effectively subsidizes its creditors and affiliates at the expense of owners.
RichFakir rates Ishan Dyes and chemicals Ltd's business quality as poor — 21/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Ishan Dyes and chemicals Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Ishan Dyes and chemicals Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Ishan Dyes and chemicals Ltd's fair value is about ₹2 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →